2月6日,全球领先的制药公司阿斯利康(AstraZeneca)在披露其2024年度财报的同时,宣布已收到深圳海关出具的《移送审查起诉告知书》以及《鉴定意见通知书》。据告知书内容显示,阿斯利康涉嫌偷逃进口税款,金额达90万美元。若公司被判逃税,可能会被处以至多450万美元的罚款。据深圳海关出具的《鉴定意见通知书》显示,阿斯利康涉嫌偷逃的进口税款涉及度伐利尤单抗(Imfinzi)和替西木单抗(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.